ClinicalTrials.gg
CompletedNCT03099148Updated Oct 17, 2023Results posted

A Study of LY3337641 in Healthy Participants

A Phase 1 interventional study of Reference Formulation (R) and LY3337641 (T1) in Healthy, sponsored by Eli Lilly and Company. Completed at 2 sites in Singapore. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-10-17.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
29
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Study summary

The purposes of this study are to determine:

  • If there are any differences in the amount of LY3337641 in the blood/body when it is taken in different formulations. A total of 3 different formulations of LY3337641 are being tested.
  • How a high-fat meal affects the amount of LY3337641 in the blood/body.
  • How safe and well tolerated LY3337641 is.

The study has four periods. Individuals will participate in all four periods. Each period will include 4 overnight stays (5 days) in the Clinical Research Unit (CRU).

This study is expected to last up to 8 weeks. This includes the initial screening period, the study or dosing period, and the follow up period.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Are overtly healthy males or females, as determined by medical history and physical examination
  • Have a (BMI) of 18.5 to 32 kilograms per meter squared (kg/m²) inclusive
  • Have clinical laboratory test results within normal reference range for the population or investigative site
  • Are able and willing to give signed

Exclusion criteria

Exclusion Criteria:

  • Have participated, within the last 30 days, in a clinical trial involving an product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer) should have passed
  • Have significant history of or current cardiovascular, dermatological (such as eczema, psoriasis, and acne), respiratory, hepatic, renal, gastrointestinal (cholecystectomy is not acceptable), endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
  • Have used or intend to use over-the-counter or prescription medication, including herbal medications, within 14 days prior to planned dosing
  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
29 participants (actual)

Study arms

  • Experimental
    LY3337641 (R-fasted)

    A single, PO dose of reference formulation (R) given orally with water after an overnight fast in one of four periods.

    Drug: Reference Formulation (R)

  • Experimental
    LY3337641 (T1-fasted)

    A single, PO dose of LY3337641(20mg) test formulation 1 (T1) given orally with water after an overnight fast in one of four periods.

    Drug: LY3337641 (T1)

  • Experimental
    LY3337641 (T1-fed)

    A single, PO dose of LY3337641 (20mg) test formulation 1 (T1) given orally with water after a high fat meal in one of four periods.

    Drug: LY3337641 (T1)

  • Experimental
    LY3337641 (T2-fasted)

    A single, PO dose of LY3337641 (20 mg) test formulation 2 (T2) given orally with water after an overnight fast in one of four periods.

    Drug: LY3337641 (T2)

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641

    Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641

    Time frame: Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose

  2. Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641

    Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of LY3337641

    Time frame: Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose

07

Results

Posted Oct 17, 2023

Participant flow

4 period, 4 sequence, randomized crossover study with at least 5 days between doses.

Period 1
Participant flow — Period 1
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7778
Received at least 1 dose of study drug7778
Completed7778
Not completed0000
Wash-out
Participant flow — Wash-out
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7778
Completed7678
Not completed0100
Withdrew: Scheduling conflict0100
Period 2
Participant flow — Period 2
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7678
Completed7678
Not completed0000
Wash-out
Participant flow — Wash-out
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7678
Completed7578
Not completed0100
Withdrew: Adverse event0100
Period 3
Participant flow — Period 3
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7578
Completed7578
Not completed0000
Wash-out
Participant flow — Wash-out
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7578
Completed7578
Not completed0000
Period 4
Participant flow — Period 4
MilestoneSequence ADBCSequence BACDSequence CBDASequence DCAB
Started7578
Completed7578
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641

Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641

Time frame:
Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY3337641
nanograms per milliliter (ng/mL)Reference Formulation (R-fasted)LY3337641 (T1-fasted)LY3337641 (T1-fed)LY3337641 (T2-fasted)
Pharmacokinetics (PK): Maximum Observed Drug Concentration (Cmax) of LY333764166.7 ± 4064.9 ± 4156.8 ± 4465.5 ± 35
PrimaryPharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641

Pharmacokinetics (PK): Area Under the Concentration versus Time Curve from Time Zero to Infinity (AUC\[0-∞\]) of LY3337641

Time frame:
Period 1,2,3,4 (Day 1): Predose, 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48 and 72 hours postdose
Reported as:
Geometric mean · nanograms*hour per milliliter (ng*h/mL)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641
nanograms*hour per milliliter (ng*h/mL)Reference Formulation (R-fasted)LY3337641 (T1-fasted)LY3337641 (T1-fed)LY3337641 (T2-fasted)
Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3337641373 ± 44371 ± 47351 ± 42361 ± 43

Adverse events

Collected over 2 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Reference Formulation (R-fasted)0/28 (0%)0/28 (0%)6/28 (21.4%)
LY3337641 (T1-fasted)0/29 (0%)0/29 (0%)4/29 (13.8%)
LY3337641 (T1-fed)0/27 (0%)0/27 (0%)5/27 (18.5%)
LY3337641 (T2-fasted)0/27 (0%)0/27 (0%)2/27 (7.4%)
Most frequent other events
Most frequent other events
EventReference Formulation (R-fasted)LY3337641 (T1-fasted)LY3337641 (T1-fed)LY3337641 (T2-fasted)
Catheter site bruiseGeneral disorders1/281/293/270/27
Catheter site swellingGeneral disorders1/282/292/271/27
HeadacheNervous system disorders2/280/290/270/27
ErythemaSkin and subcutaneous tissue disorders2/280/290/270/27
Catheter site erythemaGeneral disorders1/282/291/271/27

Baseline characteristics

Age, Continuous
Age, Continuous(years)Overall
Mean38 ± 7.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall
Female1
Male28
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall
Hispanic or Latino0
Not Hispanic or Latino29
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall
American Indian or Alaska Native0
Asian29
Native Hawaiian or Other Pacific Islander0
Black or African American0
White0
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall
Singapore29
Body Mass Index (BMI)
Body Mass Index (BMI)(kilograms per meter squared)Overall
Mean25.53 ± 2.69
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.
    Singapore, 117597, Singapore
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Singapore, Singapore
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2017 to primary completion in May 2017, 1 month.

Results were first posted in Oct 2023, 6 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2017
First posted
Apr 4, 2017
StartActual
Apr 4, 2017
Primary completionActual
May 31, 2017
CompletionActual
May 31, 2017
Results first posted
Oct 17, 2023
Last update
Oct 17, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 17, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03099148
Responsible party
Sponsor
First posted
Apr 4, 2017
Start date
Apr 4, 2017
Primary completion
May 31, 2017
Completion
May 31, 2017
Results posted
Oct 17, 2023
Last update
Oct 17, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poseltinib

Start the discussion